NEW YORK (GenomeWeb News) – The National Cancer Institute is making two newly developed cancer biomarker technologies available for licensing, one for early diagnosis of ovarian cancer and one to predict patient response to chemotherapy.
 
The NCI’s Cell and Cancer Biology branch today issued details about the technology that addresses ovarian cancer, which it said is the fifth most common cancer in US women, and which killed more than 15,000 women in the US in 2006, making it three times more deadly than breast cancer.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.